Results. 72 cases of definite Candida IE were identified of which 33 had additional data on antifungal therapy available. The most common infecting species were C. albicans (n = 13) and C. parapsilosis (n = 12). Most patients received either an amphotericin B based regimen (33%) or an echinocandin based regimen (42%). Nearly half received combination antifungal therapy (45%) and surgical therapy was used in 13 patients (39%). There was no difference in either 42 day or 1 year mortality between those receiving an amphotericin B based regimen vs those receiving an echinocandin based regimen (36% vs 36% and 64% vs 69%, respectively, p = 1).
Conclusion. This is one of the largest prospective series of Candida endocarditis patients to date. In this cohort, there was no difference in mortality with echinocandin based therapy as compared to amphotericin B based therapy. This study is limited by small sample size and observational data, however it lends support to the current recommendation of echinocandin based therapy as a viable treatment option for Candida endocarditis. 
